BR112022012246A2 - Uso de lemborexant para tratar insônia - Google Patents
Uso de lemborexant para tratar insôniaInfo
- Publication number
- BR112022012246A2 BR112022012246A2 BR112022012246A BR112022012246A BR112022012246A2 BR 112022012246 A2 BR112022012246 A2 BR 112022012246A2 BR 112022012246 A BR112022012246 A BR 112022012246A BR 112022012246 A BR112022012246 A BR 112022012246A BR 112022012246 A2 BR112022012246 A2 BR 112022012246A2
- Authority
- BR
- Brazil
- Prior art keywords
- lemborexant
- pharmaceutically acceptable
- acceptable salt
- dose
- child
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
USO DE LEMBOREXANT PARA TRATAR INSÔNIA. Trata-se de métodos para tratar insônia que compreendem administrar oralmente uma forma de dosagem que compreende lemborexant ou um sal farmaceuticamente aceitável do mesmo a um paciente que necessita do mesmo em uma dose diária única na faixa de 5 mg a 10 mg de lemborexant ou uma dose equivalente de um sal farmaceuticamente aceitável do mesmo, desde que a dose máxima seja 5 mg uma vez por dia de lemborexant ou uma dose equivalente de um sal farmaceuticamente aceitável do mesmo quando o paciente tem insuficiência hepática moderada classificada em classe de Child-Pugh B sob a Classificação Child-Pugh.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951638P | 2019-12-20 | 2019-12-20 | |
| PCT/US2020/065891 WO2021127359A1 (en) | 2019-12-20 | 2020-12-18 | Use of lemborexant for treating insomnia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012246A2 true BR112022012246A2 (pt) | 2022-08-30 |
Family
ID=74191874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012246A BR112022012246A2 (pt) | 2019-12-20 | 2020-12-18 | Uso de lemborexant para tratar insônia |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230051268A1 (pt) |
| EP (1) | EP4076463A1 (pt) |
| JP (1) | JP2023508011A (pt) |
| KR (1) | KR20220119065A (pt) |
| CN (1) | CN115003305A (pt) |
| AU (1) | AU2020408557A1 (pt) |
| BR (1) | BR112022012246A2 (pt) |
| CA (1) | CA3165481A1 (pt) |
| MX (1) | MX2022007304A (pt) |
| TW (1) | TW202137986A (pt) |
| WO (1) | WO2021127359A1 (pt) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2220036A1 (en) | 1995-05-05 | 1996-11-07 | Human Genome Sciences, Inc. | Human neuropeptide receptor |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| PE20131162A1 (es) | 2010-09-22 | 2013-10-19 | Eisai Randd Man Co Ltd | Compuestos de ciclopropano como antagonistas del receptor de orexina |
| RU2617696C2 (ru) | 2012-02-17 | 2017-04-26 | ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД | Способы и соединения, которые можно использовать для синтеза антагонистов рецепторов орексина-2 |
| ES2843952T3 (es) * | 2014-10-23 | 2021-07-21 | Eisai R&D Man Co Ltd | Composiciones para tratar el insomnio |
-
2020
- 2020-12-18 AU AU2020408557A patent/AU2020408557A1/en active Pending
- 2020-12-18 EP EP20842786.4A patent/EP4076463A1/en active Pending
- 2020-12-18 KR KR1020227023903A patent/KR20220119065A/ko unknown
- 2020-12-18 US US17/757,672 patent/US20230051268A1/en active Pending
- 2020-12-18 JP JP2022537669A patent/JP2023508011A/ja active Pending
- 2020-12-18 MX MX2022007304A patent/MX2022007304A/es unknown
- 2020-12-18 CA CA3165481A patent/CA3165481A1/en active Pending
- 2020-12-18 CN CN202080094379.0A patent/CN115003305A/zh active Pending
- 2020-12-18 WO PCT/US2020/065891 patent/WO2021127359A1/en unknown
- 2020-12-18 BR BR112022012246A patent/BR112022012246A2/pt unknown
- 2020-12-18 TW TW109145085A patent/TW202137986A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202137986A (zh) | 2021-10-16 |
| CA3165481A1 (en) | 2021-06-24 |
| AU2020408557A1 (en) | 2022-08-11 |
| CN115003305A (zh) | 2022-09-02 |
| JP2023508011A (ja) | 2023-02-28 |
| EP4076463A1 (en) | 2022-10-26 |
| KR20220119065A (ko) | 2022-08-26 |
| US20230051268A1 (en) | 2023-02-16 |
| WO2021127359A1 (en) | 2021-06-24 |
| MX2022007304A (es) | 2022-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
| BR112016002465A2 (pt) | terapia da combinação para o tratamento de câncer | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112019002513A2 (pt) | uso e dosagem de agentes terapêuticos para endometriose | |
| BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| BR112019002461A2 (pt) | regime de dosagem para tratamento de tumores sólidos | |
| CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MX2021002322A (es) | Nuevos metodos. | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| CO2019003808A2 (es) | Composición farmacéutica que comprende antagonista receptor de mineralocorticoides y uso de la misma | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| BR112022012246A2 (pt) | Uso de lemborexant para tratar insônia | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
| AR111803A1 (es) | Derivado de ciclopentan[g]quinazolin-4-ona y su empleo en el tratamiento de cáncer resistente al platino | |
| BR112022003419A2 (pt) | Forma de dosagem oral sólida compreendendo naproxeno e vitamina b12 | |
| AR116592A1 (es) | Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| AR113906A1 (es) | Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple |